Updated

Novo Nordisk announced on October 20, 2026, that its experimental next-generation obesity drug CagriSema demonstrated 25 percent weight loss in women in late-stage analysis. The injectable treatment showed improvement over the company's blockbuster GLP-1 obesity drug Wegovy, indicating progress in Novo's pipeline for weight management treatments and positioning the Danish pharmaceutical company to compete in the lucrative obesity medication market.